Skip to main content

What the FDA labels say about taking them together

Camizestrant and palbociclib

Camizestrant's FDA label of September 4, 2026 names palbociclib in its drug interactions section; the palbociclib labels PlainMeds reads (2) do not name camizestrant. The camizestrant label: “If concomitant use with a moderate CYP3A inducer cannot be avoided, dose adjustment is needed when ETCAMAH is given in combination with abemaciclib or palbociclib.”

Check it at the source: the camizestrant FDA label on DailyMed (effective September 4, 2026, AstraZeneca Pharmaceuticals LP); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the camizestrant label say about palbociclib?

Camizestrant label, drug interactions

If concomitant use with a moderate CYP3A inducer cannot be avoided, dose adjustment is needed when ETCAMAH is given in combination with abemaciclib or palbociclib.

Source: FDA drug label (ETCAMAH), AstraZeneca Pharmaceuticals LP, effective September 4, 2026 (SPL set c54223d3-f3c7-4186-afa0-429d84805826), via openFDA; the full label on DailyMed

What does the palbociclib label say about camizestrant?

Palbociclib's label (effective July 2, 2026) and its 1 other brand-application label do not name camizestrant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Camizestrant generic labelers
0Palbociclib generic labelers
CamizestrantPalbociclib
Labeled forn/aBreast cancer
Boxed warningYesNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?